Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Assess the Safety and Tolerability of the Combination of Oral ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT06351644 is registered in ClinicalTrials.gov with Adriana Rossi as lead sponsor.

NCT NCT06351644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06351644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Assess the Safety and Tolerability of the Combination of Oral ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Adriana Rossi
Phase
Phase 1/2
Overall status
Terminated
Start date
October 2, 2024
Completion date
April 28, 2025
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma